# Single Dose Study of ALZ-801 Prototype Tablets

> **NCT04585347** · PHASE1 · COMPLETED · sponsor: **Alzheon Inc.** · enrollment: 12 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** ALZ-801 170 mg Fasting
- **DRUG:** ALZ-801 205 mg Fasting
- **DRUG:** ALZ-801 205 mg After Food
- **DRUG:** ALZ-801 342 mg Fasting

## Key facts

- **NCT ID:** NCT04585347
- **Lead sponsor:** Alzheon Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-16
- **Primary completion:** 2015-11-13
- **Final completion:** 2015-11-13
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585347, "Single Dose Study of ALZ-801 Prototype Tablets". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04585347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*